CDK19-Selective Inhibitors for Triple-Negative Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for triple-negative breast cancer (TNBC) are limited by the non-specificity and toxicity of chemotherapy, and compounds that inhibit CDK19 and CDK8 often result in undesired side effects due to the wider tissue distribution of CDK8, necessitating the development of compounds that selectively inhibit CDK19.
Innovation Solution
The disclosure provides compounds of formula (I) that selectively inhibit CDK19 over CDK8, which are designed to minimize side effects by targeting specific structures and substituents, allowing for the development of pharmaceutical compositions for treating TNBC and other cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds that non-selectively inhibit CDK19 and CDK8 are used, then anti-cancer properties are achieved, but undesired side effects occur due to CDK8 inhibition
Solution Approach 1:
The patent segments the dual CDK19/CDK8 inhibition function into selective CDK19 inhibition only. The compound is designed to specifically target CDK19 while avoiding CDK8, thereby maintaining anti-cancer efficacy against TNBC while eliminating the gastrointestinal side effects associated with CDK8 inhibition in colon cells.
Solution Approach 2:
The patent applies local quality by creating compounds with specific molecular structures (Formula I variants) that exhibit selective binding affinity for CDK19 over CDK8. This selective inhibition profile allows the compound to exert its anti-cancer effect locally in CDK19-expressing cancer cells while sparing CDK8-expressing normal cells, particularly in the gastrointestinal tract.
2Adaptability or versatility
If CDK8 is inhibited, then broader anti-cancer coverage is achieved, but gastrointestinal side effects increase due to high CDK8 expression in the colon
Solution Approach 1:
The patent segments the kinase inhibition target from CDK8 to CDK19 specifically. By focusing inhibition on CDK19 rather than CDK8, the compound achieves adaptability to cancer cells (which express CDK19) while avoiding harm to gastrointestinal tissues (which express high levels of CDK8).
Solution Approach 2:
The compound exhibits local quality through selective pharmacological action: it inhibits CDK19 in cancer cells where it is oncogenic, but does not inhibit CDK8 in normal gastrointestinal cells where it is protective. This selective action profile resolves the contradiction between broad anti-cancer coverage and gastrointestinal safety.
3Reliability
If chemotherapy is used to treat TNBC, then therapeutic intervention is provided, but non-specific cytotoxicity and high toxicity occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I and its variants) that selectively target CDK19 in cancer cells. This selective inhibition provides therapeutic intervention in TNBC while minimizing systemic toxicity to normal cells, unlike non-specific chemotherapy agents that affect all rapidly dividing cells.
Solution Approach 2:
The patent uses CDK19 as an intermediary target that is specifically upregulated in TNBC cells but not in normal cells. By targeting this intermediary molecule rather than directly attacking all dividing cells (as chemotherapy does), the compound achieves therapeutic effect with reduced systemic toxicity.
Data Source
AI summary
Provided herein are compounds or pharmaceutically acceptable salts thereof, having a structure of formula (I): wherein substituents are as described herein. Also provided is a pharmaceutical composition comprising a compound or pharmaceutically acceptable salt having a structure of formula (I). Further provided are a method of inhibiting cyclin dependent kinase 19 (CDK19) a method of treating cancer (e.g., breast cancer) with the disclosed compounds.